S&P 500
(1.03%) 5 180.74 points
Dow Jones
(0.46%) 38 852 points
Nasdaq
(1.19%) 16 349 points
Oil
(0.18%) $78.62
Gas
(-1.50%) $2.16
Gold
(-0.11%) $2 328.60
Silver
(-0.34%) $27.52
Platinum
(0.36%) $968.40
USD/EUR
(0.09%) $0.929
USD/NOK
(0.20%) $10.85
USD/GBP
(0.08%) $0.797
USD/RUB
(0.00%) $91.35

Actualizaciones en tiempo real para Infant Bacterial [IBT-B.ST]

Bolsa: STO Sector: Healthcare Industria: Biotechnology
Última actualización6 may 2024 @ 11:08

1.58% SEK 89.80

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 11:08):

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden...

Stats
Volumen de hoy 349.00
Volumen promedio 6 100.00
Capitalización de mercado 1.17B
EPS SEK0 ( 2024-02-07 )
Last Dividend SEK0 ( N/A )
Next Dividend SEK0 ( N/A )
P/E -9.03
ATR14 SEK1.043 (1.16%)

Infant Bacterial Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Infant Bacterial Finanzas

Annual 2023
Ingresos: SEK77 000.00
Beneficio Bruto: SEK77 000.00 (100.00 %)
EPS: SEK-9.95
FY 2023
Ingresos: SEK77 000.00
Beneficio Bruto: SEK77 000.00 (100.00 %)
EPS: SEK-9.95
FY 2022
Ingresos: SEK0
Beneficio Bruto: SEK0 (0.00 %)
EPS: SEK-5.80
FY 2021
Ingresos: SEK0.00
Beneficio Bruto: SEK0.00 (0.00 %)
EPS: SEK-0.429

Financial Reports:

No articles found.

Infant Bacterial

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico